ouabain has been researched along with zatebradine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, S; Furukawa, Y; Hashimoto, K; Xue, YX | 1 |
| Grenett, HE; Huang, J; Ku, DD; Urthaler, F; Wolkowicz, PE; Wu, HC | 1 |
2 other study(ies) available for ouabain and zatebradine
| Article | Year |
|---|---|
Effects of zatebradine on ouabain-, two-stage coronary ligation- and epinephrine-induced ventricular tachyarrhythmias.
Topics: Animals; Benzazepines; Cardiotonic Agents; Dogs; Dose-Response Relationship, Drug; Epinephrine; Female; Heart Rate; Ligation; Male; Ouabain; Tachycardia, Ventricular; Vasoconstrictor Agents | 1996 |
A pharmacological model for calcium overload-induced tachycardia in isolated rat left atria.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Benzazepines; Boron Compounds; Calcium; Calcium Channel Agonists; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Heart Atria; In Vitro Techniques; Male; Ouabain; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ryanodine; Tachycardia | 2007 |